NEW YORK, Feb. 22 - Start-up systems-biology company Beyond Genomics on Friday said that Micromass UK Limited, a wholly-owned subsidiary of Waters, will supply its leading mass spectrometry technologies in its own systems biology drug-discovery platform.

Terms of the deal call for Waters to make an equity investment in Beyond Genomics in exchange for provisions that Beyond Genomics will buy Micromass products. The agreement also says that Micromass will have the option to license certain IP from Beyond Genomics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.